Pharmacyclics (PCYC) stops RESONATE (that's Phase 3 ibrutinib versus ofatumumab in relapsed or refractory CLL or SLL) early on the IDMC's recommendation, as Imbruvica hits its primary and key secondary endpoints.
Imbruvica shows statistically significant PFS and OS superiority.
Safety profile is "acceptable and consistent with prior clinical experience."
FDA and EMA have been notified (EMA by Janssen, JNJ). (PR)